Relmada Therapeutics, Inc. RLMD Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s accrued expenses?
- Relmada Therapeutics, Inc. (RLMD) reported accrued expenses of $7.16M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Relmada Therapeutics, Inc.'s accrued expenses increased by 80.5% year-over-year, from $3.97M to $7.16M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s accrued expenses has grown at a 107.6% compound annual growth rate (CAGR), from $126.2K to $4.86M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.